Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer’s disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late-middle-aged people, we demonstrated an association between apolipoprotein E (APOE) ε4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a presymptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE ε4 homozygotes, heterozygotes and noncarriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE ε4 carriers than non-carriers in some of the AD-affected brain regions. We postulate the higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“In addition to its other biological properties, APOE is the major transporter of cholesterol in the blood and central nervous system (Mahley, 1988), and the APOE E4 isoform is associated with a higher risk of AD (Corder et al., 1993; Farrer et al., 1997) and amyloid-β neuropathology (Ohm et al.,…”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“With the rising number of people living to older ages, the prevalence and cost of AD is projected to become overwhelming (Hebert et al., 2003).”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 3×
“Epidemiological studies suggest that elevated serum total cholesterol during midlife, but not late-life, is associated with increased risk of AD (Kivipelto et al., 2001; Klag et al.,1993;Martin et al.,1986;Mielke et al., 2005) and AD neuropathology (Launer et al.”
BackgroundBrain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 7×
“Venous blood samples were drawn and APOE genotypes characterized as previously described (Crook et al., 1994; Reiman et al., 1996).”
MethodInfluentialSelf-citationFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 4×
“…that higher levels are also associated with lower CMRgl in frontal regions known to be preferentially affected by normal aging (Kuhl et al., 1982; Loessner et al., 1995; Reiman et al., 2004; Salmon et al., 1991), and to compare these associations in our APOE ɛ4 carrier and non-carrier groups.”
BackgroundResultInfluentialSelf-citationReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 4×
“More recently, we found an association between APOE ɛ4 gene dose and PET measurements of fibrillar amyloid-β burden, suggesting that this brain-imaging measurement could also be used as a quantitative pre-symptomatic endophenotype for the assessment of putative AD riskmodifiers (Reiman et al., 2009).”
BackgroundInfluentialSelf-citationAlexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
Self-citationReiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467 · cited 4×
“Just as we have proposed the use of pre-symptomatic brainimaging endophenotypes to assess the effects of putative AD risk modifiers, we have proposed using brain-imaging and other biomarker measurements to evaluate pre-symptomatic treatments without having to study thousands of cognitively normal volunteers or wait ma…”
BackgroundMethodInfluentialSelf-citationHigh total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 3×
“…associated with a reduced risk of AD (Green et al., 2005; Haag et al., 2009), and there is some debate as to whether hydrophilic compared to lipophilic statins are more effective at decreasing brain amyloid and reducing the risk of AD (Haag et al., 2009; Sparks et al., 2002; Wolozin et al., 2007).”
BackgroundResultHeart Protection Study Collaborative Group (2011) · The Lancet · doi:10.1016/s0140-6736(11)61125-2 · Cited by 373
Kuhl, D. E., Metter, E. J., Riege, W. H., & Phelps, M. E. (1982) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1982.15 · Cited by 338 · cited 4×
“…the possibility that higher levels are also associated with lower CMRgl in frontal regions known to be preferentially affected by normal aging (Kuhl et al., 1982; Loessner et al., 1995; Reiman et al., 2004; Salmon et al., 1991), and to compare these associations in our APOE ɛ4 carrier and…”
BackgroundResultInfluentialLangbaum, J. B. S., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., Alexander, G. E., Foster, N. L., Weiner, M. W., Koeppe, R. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.072 · Cited by 279 · cited 4×
“…normal, late middle-aged persons are associated with lower CMRgl in brain regions known to be preferentially affected by AD (Alexander et al., 2002; Langbaum et al., 2009), to explore the possibility that higher levels are also associated with lower CMRgl in frontal regions known to be…”
BackgroundMethodInfluentialSelf-citationOhm, T. G., Kirca, M., Bohl, J., Scharnagl, H., Groβ, W., & März, W. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00596-w · Cited by 157
Kuo, Y.-M., Webster, S., Emmerling, M. R., De Lima, N., & Roher, A. E. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00014-3 · Cited by 122 · cited 2×
“Serum lipoprotein cholesterol profiles and distribution among lipoproteins were determined by high performance gel filtration chromatography (Kuo et al., 1998).”
MethodLi, L., Cao, D., Desmond, R., Rahman, A., Lah, J. J., Levey, A. I., & Zamrini, E. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000164271 · Cited by 45 · cited 1×
“…duration of treatment and age in which treatment was started, particularly because findings from some studies suggest that statin use may be most effective at reducing incident AD in persons younger than 80 years of age (Cramer et al., 2008; Li et al., 2006, 2007, 2008; Rockwood et al., 2002).”
Background
Cited by
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“A relationship of this FDG pattern to serum cholesterol and to an aggregate cholesterolrelated genetic score in middle age has also been reported (Reiman et al. 2008, 2010).”
BackgroundApolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
Self-citationBrain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236
Metadata
- Authors
- Reiman, E. M., Chen, K., Langbaum, J. B. S., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., & Caselli, R. J.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 49
- Issue
- 1
- Pages
- 169-176
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2099386456
- Cited by
- 70
- References
- 20
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.